Background:  ODYSSEY Outcomes  is  a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effect of alirocumab (SAR236553/REGN727) on the occurrence of cardiovascular events in patients who have recently experienced an acute coronary syndrome (ACS). This multicenter phase 3 study has randomized approximately 18’000 patients to receive biweekly injections of alirocumab (75-150 mg) or matching placebo in addition to standard high effective statin therapy. Qualifying patients fulfill one of the following criteria: LDL-C ≥ 1.81 mmol/L, non-high-density lipoprotein cholesterol ≥ 2.59 mmol/L, or apolipoprotein B ≥ 80 mg/dL. The ODYSSEY Outcomes trial tests the hypothesis that treatment with alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), improves cardiovascular outcomes after ACS. Trial Registration No: NCT01663402 (clinicaltrials.gov) Link  Trial Status: Active, not recruiting  Enrolling Centers:  Worldwide: multicentric  Core Study Team: 
© Christian Mueller, 2012 - 2017  │  Disclaimer  │  Imprint  │  Webmaster │ Last Update: December 2017
Dr. Ina Ferel-Harwerth Dr. Samyut Shresta Prof. Christian Müller MIchael Freese Sanela Barac Therese Rinderknecht Deborah Müller Ayman Alhussini Claudia Stelzig Home News Team Studies Publications Events Cooperations Contact